Posted by Michael Wonder on 08 Mar 2018
NICE u-turn on treatment for giant cell arteritis
8 March 2018 - Roche/Chugai’s RoActemra has now won the backing of NICE for the treatment of eligible patients with giant cell arteritis.
The drug was initially rejected in draft guidelines published in November, after the appraisal committee highlighted “substantial uncertainties” in the evidence on how long patients would have to take the treatment and what the long-term benefits are.
Almost 15,000 UK patients develop giant cell arteritis – a potentially life-threatening form of vasculitis that results in inflammation of blood vessels – every year.
